Tag: niemann pick disease market trends

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Niemann-Pick Disease (NPD) Market Forecast: What Market Value Is Expected By 2030?

The market for Niemann-Pick Disease (NPD) has experienced substantial expansion recently, and this upward trajectory is projected to continue. Estimates indicate the market will advance from $1.07 billion in 2025 to $1.19 billion in 2026, reflecting a compound annual growth rate of 11.1%. Historical drivers for this market’s development included the scarcity of therapeutic options, a lack of widespread understanding regarding the condition, prolonged periods for diagnosis, the necessity of focusing on symptom alleviation, and the significant financial burden associated with treatment.

The Niemann-Pick Disease (NPD) market is poised for substantial expansion, projected to reach $1.79 billion by 2030, reflecting a compound annual growth rate of 10.8%. This upward trajectory is fueled by several key factors: augmented investment in rare disease research, advancements in gene therapy methodologies, the broader implementation of newborn screening initiatives, escalating healthcare spending, and favorable regulatory provisions. Throughout this projected period, significant market developments are anticipated, including a greater emphasis on early genetic detection, an increased number of orphan drug development projects, enhanced patient advocacy and awareness campaigns, progress in enzyme replacement and substrate reduction treatments, and refined multidisciplinary strategies for managing the disease.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23457&type=smp

Niemann-Pick Disease (NPD) Market Expansion Drivers: What Is Shaping Future Growth?

The niemann-pick disease (NPD) market’s expansion is anticipated to be significantly influenced by the increasing utilization of gene therapy. This therapeutic approach, which involves altering or influencing an individual’s genetic makeup for disease prevention or treatment, is experiencing a surge in development, fueled by sophisticated genetic engineering capabilities that allow for accurate and efficient gene alterations, thereby enhancing therapeutic results for inherited conditions. Gene therapy contributes to managing niemann-pick disease (NPD) by addressing the root genetic defects, with the goal of rectifying the enzyme insufficiencies responsible for the condition and boosting cellular performance. As an illustration, by January 2024, as reported by the American Society of Gene and Cell Therapy, a prominent US entity in the gene and cell therapy sector, gene therapies undergoing Phase III evaluation saw a 10% increase during the final quarter of 2023 compared to the preceding quarter, marking the inaugural rise since the third quarter of 2022. Consequently, the escalating acceptance of gene therapy serves as a primary catalyst for the growth observed in the niemann-pick disease (NPD) market.

Niemann-Pick Disease (NPD) Market Segment Outlook: Which Categories Are Expanding The Fastest?

The niemann-pick disease (npd) market covered in this report is segmented –

1) By Type: Niemann-Pick Disease Type A, Niemann-Pick Disease Type B, Niemann-Pick Disease Type C

2) By Treatment Type: Drugs, Physical Therapy, Other Treatment Types

3) By Route Of Administration: Oral, Intravenous, Subcutaneous

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

5) By End-User: Hospitals, Clinics, Homecare Settings

Subsegments:

1) By Niemann-Pick Disease Type A: Infantile-Onset Niemann-Pick Disease, Neurodegenerative Niemann-Pick Disease, Acute Visceral Niemann-Pick Disease, Severe Lysosomal Storage Disorder

2) By Niemann-Pick Disease Type B: Late-Onset Niemann-Pick Disease, Non-Neurological Niemann-Pick Disease, Chronic Visceral Niemann-Pick Disease, Mild Lysosomal Storage Disorder

3) By Niemann-Pick Disease Type C: Early-Onset Niemann-Pick Disease, Juvenile Niemann-Pick Disease, Adult-Onset Niemann-Pick Disease, Progressive Neurodegenerative Niemann-Pick Disease

Niemann-Pick Disease (NPD) Market Strategic Trends: What Is Defining The Next Phase Of Growth?

Within the Niemann-Pick disease (NPD) landscape, key industry players are concentrating their efforts on pioneering novel therapeutic approaches, including combination treatments, with the objective of bolstering treatment effectiveness and elevating patient prognoses. The concept of combination therapy entails the concurrent application of multiple medicinal compounds or therapeutic regimens to confront a specific ailment or health concern. This strategy is designed to boost therapeutic impact and mitigate the potential for treatment resistance that can arise with single-agent interventions. Illustrating this, in September of 2024, Zevra Therapeutics Inc., a biopharmaceutical entity headquartered in the United States, secured approval from the U.S. Food and Drug Administration (FDA) for its product, MIPLYFFA, when utilized alongside miglustat for the management of the neurological symptoms associated with Niemann-Pick disease type C (NPC) in individuals spanning from pediatric to adult age groups, provided they are two years of age or older. MIPLYFFA, also known as arimoclomol, functions by stimulating the generation of heat shock proteins (HSPs), elements that contribute to the clearance of detrimental lipid deposits and offer neuroprotection against cellular injury. Concurrently, miglustat operates by impeding glucosylceramide synthase, thus leading to a reduction in lipid accumulation. The synergistic action of these two treatments collectively aids in decelerating the advancement of neurological deterioration observed in individuals afflicted with NPC.

Niemann-Pick Disease (NPD) Market Key Companies And Competitive Benchmarking

Major companies operating in the niemann-pick disease (npd) market are Sanofi S.A., Mayo Clinic, Cincinnati Children’s Hospital Medical Center, Boston Children’s Hospital, Mallinckrodt Pharmaceuticals plc, Myriad Genetics, CENTOGENE N.V., The Florey Institute of Neuroscience and Mental Health, National Organization for Rare Disorders (NORD), Evox Therapeutics Limited, Bloomsbury Genetic Therapies Ltd., Cyclo Therapeutics Inc., CarelonRx, Rainbow Children’s Hospital, Vtesse Inc., Orphazyme A/S, Zebra Biologics, Sarepta Therapeutics Inc., Takeda Pharmaceutical Company Limited, Pfizer Inc., Novartis International AG, Ultragenyx Pharmaceutical Inc., Passage Bio, Amicus Therapeutics Inc., PTC Therapeutics, SOM Biotech, ENDECE, StrideBio, Mandos Health, BioMarin Pharmaceutical Inc.

Access The Complete Niemann-Pick Disease (NPD) Market Report:

https://www.thebusinessresearchcompany.com/report/niemann-pick-disease-npd-global-market-report

Niemann-Pick Disease (NPD) Market Regional Outlook: Where Are The Largest Opportunities Located?

North Americawas the largest region in the niemann-pick disease (NPD) market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the niemann-pick disease (npd) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Niemann-Pick Disease (NPD) Market’s Market Value Anticipated To Evolve From 2026 To 2030?

The niemann-pick disease (npd) market has observed rapid expansion in its valuation over recent years. Forecasts indicate this market will increase from $1.07 billion in 2025 to $1.19 billion in 2026, reflecting a compound annual growth rate (CAGR) of 11.1%. Historically, this market expansion can be linked to aspects such as limited treatment availability, low disease awareness, delayed diagnosis rates, a dependence on symptomatic management, and high treatment costs.

The niemann-pick disease (npd) market size is anticipated to undergo significant expansion in the coming years. It is projected to achieve a valuation of $1.79 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.8%. This growth throughout the forecast period can be attributed to increased funding for rare diseases, advancements in gene therapy research, the expansion of newborn screening initiatives, rising healthcare expenditures, and supportive regulatory frameworks. Prominent trends expected during this period include a greater focus on early genetic screening, the broadened development of orphan drugs, an increase in patient advocacy and awareness programs, the growth of enzyme replacement and substrate reduction therapies, and improved multidisciplinary disease management strategies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23457&type=smp

What Are The Main Drivers Accelerating The Growth Of The Niemann-Pick Disease (NPD) Market?

The increasing acceptance of gene therapy is anticipated to boost the niemann-pick disease (NPD) market’s expansion in the future. Gene therapy, a medical approach, entails altering or managing an individual’s genes to address or avert illnesses. Its rise can be attributed to advancements in genetic engineering, which facilitate accurate and potent gene modifications, thereby enhancing therapeutic results for genetic conditions. For niemann-pick disease (NPD), gene therapy aids treatment by targeting the fundamental genetic mutations, with the goal of rectifying the enzyme insufficiencies responsible for the condition and enhancing cellular operations. As an illustration, in January 2024, data from the American Society of Gene and Cell Therapy, a US-based organization dedicated to gene and cell therapy, indicated that the count of gene therapies undergoing Phase III trials saw a 10% increase in the fourth quarter of 2023 when compared to the prior quarter, marking the initial rise since the third quarter of 2022. Consequently, the increasing embrace of gene therapy is propelling the expansion of the niemann-pick disease (NPD) market.

What Are The Core Segment Classifications In The Niemann-Pick Disease (NPD) Market?

The niemann-pick disease (npd) market covered in this report is segmented –

1) By Type: Niemann-Pick Disease Type A, Niemann-Pick Disease Type B, Niemann-Pick Disease Type C

2) By Treatment Type: Drugs, Physical Therapy, Other Treatment Types

3) By Route Of Administration: Oral, Intravenous, Subcutaneous

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

5) By End-User: Hospitals, Clinics, Homecare Settings

Subsegments:

1) By Niemann-Pick Disease Type A: Infantile-Onset Niemann-Pick Disease, Neurodegenerative Niemann-Pick Disease, Acute Visceral Niemann-Pick Disease, Severe Lysosomal Storage Disorder

2) By Niemann-Pick Disease Type B: Late-Onset Niemann-Pick Disease, Non-Neurological Niemann-Pick Disease, Chronic Visceral Niemann-Pick Disease, Mild Lysosomal Storage Disorder

3) By Niemann-Pick Disease Type C: Early-Onset Niemann-Pick Disease, Juvenile Niemann-Pick Disease, Adult-Onset Niemann-Pick Disease, Progressive Neurodegenerative Niemann-Pick Disease

What Trends Are Influencing The Niemann-Pick Disease (NPD) Market?

Major companies within the NGS oncology market are directing their efforts toward creating innovative solutions, such as liquid biopsy research assays, to facilitate non-invasive, real-time cancer detection and monitoring through the analysis of circulating tumor DNA. A liquid biopsy research assay is a diagnostic examination that scrutinizes biological fluids, like blood, to identify genetic mutations or other molecular indicators associated with cancer, enabling non-invasive detection and ongoing observation of the disease. For instance, in August 2024, Illumina Inc., a US-based biotechnology company specializing in next-generation sequencing technology, broadened its oncology portfolio for NovaSeq X Series users. The company now offers the newly validated high-throughput TruSight Oncology 500 (TSO 500 HT) and the updated TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2) liquid biopsy research assay. These enhanced assays allow laboratories to extend their oncology research capabilities for both tissue and liquid biopsy samples, providing improved sequencing efficiency, reduced run times, and the capability to process larger sample volumes on the NovaSeq X Series for the first time.

Which Industry Players Are Present In The Niemann-Pick Disease (NPD) Market?

Major companies operating in the niemann-pick disease (npd) market are Sanofi S.A., Mayo Clinic, Cincinnati Children’s Hospital Medical Center, Boston Children’s Hospital, Mallinckrodt Pharmaceuticals plc, Myriad Genetics, CENTOGENE N.V., The Florey Institute of Neuroscience and Mental Health, National Organization for Rare Disorders (NORD), Evox Therapeutics Limited, Bloomsbury Genetic Therapies Ltd., Cyclo Therapeutics Inc., CarelonRx, Rainbow Children’s Hospital, Vtesse Inc., Orphazyme A/S, Zebra Biologics, Sarepta Therapeutics Inc., Takeda Pharmaceutical Company Limited, Pfizer Inc., Novartis International AG, Ultragenyx Pharmaceutical Inc., Passage Bio, Amicus Therapeutics Inc., PTC Therapeutics, SOM Biotech, ENDECE, StrideBio, Mandos Health, BioMarin Pharmaceutical Inc.

Access The Complete Niemann-Pick Disease (NPD) Market Report:

https://www.thebusinessresearchcompany.com/report/niemann-pick-disease-npd-global-market-report

Which Regional Market Leads The Niemann-Pick Disease (NPD) Market?

North America was the largest region in the niemann-pick disease (NPD) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the niemann-pick disease (npd) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Niemann-Pick Disease (NPD) Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=23457&type=smp

Browse Through More Reports Similar to the Global Niemann-Pick Disease (NPD) Market 2026, By The Business Research Company

Oncology Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/oncology-drugs-market

Community Oncology Services Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/community-oncology-services-global-market-report

Oncology Companion Diagnostics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-companion-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Growth In Market Value Is Expected For The Niemann-Pick Disease (NPD) Market Between 2026 And 2030?

The niemann-pick disease (npd) market has experienced significant expansion in recent years. It is anticipated to grow from $1.07 billion in 2025 to $1.19 billion in 2026, progressing at a compound annual growth rate (CAGR) of 11.1%. Historically, the growth can be attributed to elements such as limited treatment availability, low disease awareness, delayed diagnosis rates, a reliance on symptomatic management, and high treatment costs.

The Niemann-Pick Disease (NPD) market size is projected to experience substantial growth in the upcoming years. It is expected to reach $1.79 billion by 2030, showing a compound annual growth rate (CAGR) of 10.8%. This expansion in the forecast period is attributable to increased funding for rare diseases, progress in gene therapy research, the extension of newborn screening programs, rising healthcare spending, and supportive regulatory frameworks. Key trends for the forecast period include a growing emphasis on early genetic screening, the expansion of orphan drug development, an increase in patient advocacy and awareness initiatives, the advancement of enzyme replacement and substrate reduction therapies, and enhanced multidisciplinary approaches to disease management.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23457&type=smp

Which Primary Drivers Are Impacting The Niemann-Pick Disease (NPD) Market Growth?

The increasing use of gene therapy is anticipated to drive expansion in the niemann-pick disease (NPD) market moving ahead. This medical approach focuses on altering or adjusting an individual’s genes to address or avert illnesses. Its prevalence is increasing, driven by developments in genetic engineering which allow for accurate and impactful gene alterations, leading to better results for genetic conditions. For niemann-pick disease (NPD), gene therapy offers a treatment by addressing the fundamental genetic mutations, with the goal of rectifying the enzyme shortages responsible for the condition and enhancing cellular performance. As an example, the American Society of Gene and Cell Therapy, a US-based group dedicated to gene and cell therapy, reported in January 2024 that the quantity of gene therapies in Phase III trials saw a 10% increase during the fourth quarter of 2023 compared to the preceding quarter. This marked the initial rise observed since the third quarter of 2022. Consequently, the expanding acceptance of gene therapy is fueling the expansion of the niemann-pick disease (NPD) market.

What Are The Different Segment Types In The Niemann-Pick Disease (NPD) Market Segment Breakdown?

The niemann-pick disease (npd) market covered in this report is segmented –

1) By Type: Niemann-Pick Disease Type A, Niemann-Pick Disease Type B, Niemann-Pick Disease Type C

2) By Treatment Type: Drugs, Physical Therapy, Other Treatment Types

3) By Route Of Administration: Oral, Intravenous, Subcutaneous

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

5) By End-User: Hospitals, Clinics, Homecare Settings

Subsegments:

1) By Niemann-Pick Disease Type A: Infantile-Onset Niemann-Pick Disease, Neurodegenerative Niemann-Pick Disease, Acute Visceral Niemann-Pick Disease, Severe Lysosomal Storage Disorder

2) By Niemann-Pick Disease Type B: Late-Onset Niemann-Pick Disease, Non-Neurological Niemann-Pick Disease, Chronic Visceral Niemann-Pick Disease, Mild Lysosomal Storage Disorder

3) By Niemann-Pick Disease Type C: Early-Onset Niemann-Pick Disease, Juvenile Niemann-Pick Disease, Adult-Onset Niemann-Pick Disease, Progressive Neurodegenerative Niemann-Pick Disease

Which Trends Are Shaping Growth In The Niemann-Pick Disease (NPD) Market?

Leading companies within the niemann-pick disease (NPD) market are concentrating on developing advanced treatments, such as combination therapy, to boost efficacy and improve patient outcomes. This approach involves administering two or more therapeutic agents or treatment strategies to address a disease or medical condition. The method aims to enhance effectiveness and minimize resistance to single-agent therapy (monotherapy). For instance, in September 2024, Zevra Therapeutics Inc., a US-based biopharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for MIPLYFFA, in combination with miglustat, for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in both adult and pediatric patients aged 2 years and older. MIPLYFFA (arimoclomol) functions by enhancing the production of heat shock proteins (HSPs), which assist in clearing toxic lipid buildup and protecting neurons from damage. Concurrently, miglustat inhibits glucosylceramide synthase, thereby reducing lipid accumulation. Together, these two therapies help slow the progression of neurological decline in NPC patients.

Who Are The Well-Known Companies In The Niemann-Pick Disease (NPD) Market?

Major companies operating in the niemann-pick disease (npd) market are Sanofi S.A., Mayo Clinic, Cincinnati Children’s Hospital Medical Center, Boston Children’s Hospital, Mallinckrodt Pharmaceuticals plc, Myriad Genetics, CENTOGENE N.V., The Florey Institute of Neuroscience and Mental Health, National Organization for Rare Disorders (NORD), Evox Therapeutics Limited, Bloomsbury Genetic Therapies Ltd., Cyclo Therapeutics Inc., CarelonRx, Rainbow Children’s Hospital, Vtesse Inc., Orphazyme A/S, Zebra Biologics, Sarepta Therapeutics Inc., Takeda Pharmaceutical Company Limited, Pfizer Inc., Novartis International AG, Ultragenyx Pharmaceutical Inc., Passage Bio, Amicus Therapeutics Inc., PTC Therapeutics, SOM Biotech, ENDECE, StrideBio, Mandos Health, BioMarin Pharmaceutical Inc.

Get The Full Niemann-Pick Disease (NPD) Market Report:

https://www.thebusinessresearchcompany.com/report/niemann-pick-disease-npd-global-market-report

Which Region Accounts For The Largest Portion Of The Niemann-Pick Disease (NPD) Market?

North America was the largest region in the niemann-pick disease (NPD) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the niemann-pick disease (npd) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Niemann-Pick Disease (NPD) Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/niemann-pick-disease-npd-global-market-report

Browse Through More Reports Similar to the Global Niemann-Pick Disease (NPD) Market 2026, By The Business Research Company

Oncology Drugs Market

https://www.thebusinessresearchcompany.com/report/oncology-drugs-market

Community Oncology Services Market Report

https://www.thebusinessresearchcompany.com/report/community-oncology-services-global-market-report

Oncology Companion Diagnostics Market Report

https://www.thebusinessresearchcompany.com/report/oncology-companion-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Niemann-Pick Disease (NPD) Market Over The Period 2026–2030?

The niemann-pick disease (npd) market size has experienced rapid expansion in recent years. It is anticipated to grow from $1.07 billion in 2025 to $1.19 billion in 2026, achieving a compound annual growth rate (CAGR) of 11.1%. The historical increase in this market can be linked to factors like limited treatment availability, insufficient disease awareness, prolonged diagnosis rates, reliance on symptomatic management, and elevated treatment expenses.

The market size for niemann-pick disease (npd) is anticipated to experience substantial growth in the upcoming years. It is projected to expand to $1.79 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.8%. This expansion over the forecast period is fueled by several factors, such as increased funding for rare diseases, advancements in gene therapy research, the broadening of newborn screening programs, growing healthcare expenditure, and encouraging regulatory incentives. Significant trends expected during this forecast period encompass a greater emphasis on early genetic screening, the development of more orphan drugs, an uptick in patient advocacy and awareness initiatives, progress in enzyme replacement and substrate reduction therapies, and enhanced multidisciplinary approaches to managing the disease.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23457&type=smp

Which Economic Or Industry Drivers Are Impacting The Niemann-Pick Disease (NPD) Market?

The increasing application of gene therapy is projected to fuel the expansion of the Niemann-Pick Disease (NPD) market moving forward. Gene therapy is a medical approach that involves altering or manipulating an individual’s genes to treat or prevent diseases. Its rise is attributed to advancements in genetic engineering, which enable precise and effective gene modifications, thereby improving treatment outcomes for genetic disorders. For Niemann-Pick Disease (NPD), gene therapy aids treatment by targeting the underlying genetic mutations, with the aim of correcting the enzyme deficiencies causing the disorder and enhancing cellular function. For instance, in January 2024, the American Society of Gene and Cell Therapy, a US-based organization, stated that the number of gene therapies in Phase III trials saw a 10% increase in the fourth quarter of 2023 compared to the preceding quarter, representing the first rise since the third quarter of 2022. Thus, the growing embrace of gene therapy is propelling the Niemann-Pick Disease (NPD) market’s growth.

How Is The Niemann-Pick Disease (NPD) Market Divided Into Its Major Segments?

The niemann-pick disease (npd) market covered in this report is segmented –

1) By Type: Niemann-Pick Disease Type A, Niemann-Pick Disease Type B, Niemann-Pick Disease Type C

2) By Treatment Type: Drugs, Physical Therapy, Other Treatment Types

3) By Route Of Administration: Oral, Intravenous, Subcutaneous

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

5) By End-User: Hospitals, Clinics, Homecare Settings

Subsegments:

1) By Niemann-Pick Disease Type A: Infantile-Onset Niemann-Pick Disease, Neurodegenerative Niemann-Pick Disease, Acute Visceral Niemann-Pick Disease, Severe Lysosomal Storage Disorder

2) By Niemann-Pick Disease Type B: Late-Onset Niemann-Pick Disease, Non-Neurological Niemann-Pick Disease, Chronic Visceral Niemann-Pick Disease, Mild Lysosomal Storage Disorder

3) By Niemann-Pick Disease Type C: Early-Onset Niemann-Pick Disease, Juvenile Niemann-Pick Disease, Adult-Onset Niemann-Pick Disease, Progressive Neurodegenerative Niemann-Pick Disease

What Trends Are Advancing Progress In The Niemann-Pick Disease (NPD) Market?

Key companies operating in the niemann-pick disease (NPD) market are focused on developing advanced treatments, such as combination therapy, to enhance therapeutic efficacy and improve patient outcomes. Combination therapy involves administering two or more therapeutic agents or treatment strategies to address a disease or medical condition. This approach aims to boost effectiveness and reduce resistance to single-agent therapy (monotherapy). For example, in September 2024, Zevra Therapeutics Inc., a US-based biopharmaceutical company, obtained U.S. Food and Drug Administration (FDA) approval for MIPLYFFA, in conjunction with miglustat, for managing neurological manifestations of Niemann-Pick disease type C (NPC) in adult and pediatric patients aged 2 years and older. MIPLYFFA (arimoclomol) operates by increasing the production of heat shock proteins (HSPs), which help clear toxic lipid buildup and protect neurons from damage. Simultaneously, miglustat suppresses glucosylceramide synthase, thereby reducing lipid accumulation. Together, these two therapies assist in slowing the progression of neurological decline in NPC patients.

Who Are The Prominent Organizations Shaping The Niemann-Pick Disease (NPD) Market?

Major companies operating in the niemann-pick disease (npd) market are Sanofi S.A., Mayo Clinic, Cincinnati Children’s Hospital Medical Center, Boston Children’s Hospital, Mallinckrodt Pharmaceuticals plc, Myriad Genetics, CENTOGENE N.V., The Florey Institute of Neuroscience and Mental Health, National Organization for Rare Disorders (NORD), Evox Therapeutics Limited, Bloomsbury Genetic Therapies Ltd., Cyclo Therapeutics Inc., CarelonRx, Rainbow Children’s Hospital, Vtesse Inc., Orphazyme A/S, Zebra Biologics, Sarepta Therapeutics Inc., Takeda Pharmaceutical Company Limited, Pfizer Inc., Novartis International AG, Ultragenyx Pharmaceutical Inc., Passage Bio, Amicus Therapeutics Inc., PTC Therapeutics, SOM Biotech, ENDECE, StrideBio, Mandos Health, BioMarin Pharmaceutical Inc.

Read the full niemann-pick disease (npd) market report here:

https://www.thebusinessresearchcompany.com/report/niemann-pick-disease-npd-global-market-report

What Are The Top-Performing Regions Within The Niemann-Pick Disease (NPD) Market?

North America was the largest region in the niemann-pick disease (NPD) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the niemann-pick disease (npd) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Niemann-Pick Disease (NPD) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=23457&type=smp

Browse Through More Reports Similar to the Global Niemann-Pick Disease (NPD) Market 2026, By The Business Research Company

Oncology Drugs Market

https://www.thebusinessresearchcompany.com/report/oncology-drugs-market

Community Oncology Services Global Market Report

https://www.thebusinessresearchcompany.com/report/community-oncology-services-global-market-report

Oncology Companion Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/oncology-companion-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the niemann-pick disease (npd) market from 2026–2035 with trusted insights from The Business Research Company

What long-term size projections exist for the Niemann-Pick Disease (NPD) Market covering 2026–2035?

The niemann-pick disease (npd) market size has seen rapid expansion in recent years. It is expected to grow from $1.07 billion in 2025 to $1.19 billion in 2026, achieving a compound annual growth rate (CAGR) of 11.1%. The growth observed in prior periods stems from factors like limited availability of treatments, low public awareness of the disease, delayed diagnosis rates, a reliance on symptomatic management, and high treatment costs.

The market size for niemann-pick disease (npd) is anticipated to undergo significant growth in the coming years. It is projected to expand to $1.79 billion by 2030, achieving a compound annual growth rate (CAGR) of 10.8%. This growth during the forecast period is driven by factors such as increased funding for rare diseases, advancements in gene therapy research, the expansion of newborn screening programs, rising healthcare expenditure, and supportive regulatory incentives. Prominent trends within the forecast period include a heightened focus on early genetic screening, the broadening of orphan drug development, an increase in patient advocacy and awareness programs, the growth of enzyme replacement and substrate reduction therapies, and enhanced multidisciplinary disease management approaches.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23457&type=smp

Which Drivers Are Impacting The Competitive Landscape Of The Niemann-Pick Disease (NPD) Market?

The increasing application of gene therapy is anticipated to boost the expansion of the niemann-pick disease (NPD) market in the future. This medical technique focuses on altering or controlling an individual’s genes to address or avert illnesses. Its prevalence is increasing, driven by advancements in genetic engineering, which permit accurate and efficacious gene alterations, thereby enhancing therapeutic results for hereditary conditions. For niemann-pick disease (NPD), gene therapy aids treatment by targeting the fundamental genetic mutations, endeavoring to rectify the enzyme shortages responsible for the ailment and enhance cellular operations. As an illustration, data from the US-based American Society of Gene and Cell Therapy revealed in January 2024 that gene therapies undergoing Phase III trials saw a 10% increase in the fourth quarter of 2023 relative to the prior quarter, marking the first such rise since the third quarter of 2022. Consequently, the expanding use of gene therapy is stimulating the growth within the niemann-pick disease (NPD) market.

What Segments Are Identified Within The Structure Of The Niemann-Pick Disease (NPD) Market?

The niemann-pick disease (npd) market covered in this report is segmented –

1) By Type: Niemann-Pick Disease Type A, Niemann-Pick Disease Type B, Niemann-Pick Disease Type C

2) By Treatment Type: Drugs, Physical Therapy, Other Treatment Types

3) By Route Of Administration: Oral, Intravenous, Subcutaneous

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

5) By End-User: Hospitals, Clinics, Homecare Settings

Subsegments:

1) By Niemann-Pick Disease Type A: Infantile-Onset Niemann-Pick Disease, Neurodegenerative Niemann-Pick Disease, Acute Visceral Niemann-Pick Disease, Severe Lysosomal Storage Disorder

2) By Niemann-Pick Disease Type B: Late-Onset Niemann-Pick Disease, Non-Neurological Niemann-Pick Disease, Chronic Visceral Niemann-Pick Disease, Mild Lysosomal Storage Disorder

3) By Niemann-Pick Disease Type C: Early-Onset Niemann-Pick Disease, Juvenile Niemann-Pick Disease, Adult-Onset Niemann-Pick Disease, Progressive Neurodegenerative Niemann-Pick Disease

What Upcoming Trends Are Likely To Define The Future Path Of The Niemann-Pick Disease (NPD) Market?

Major companies operating in the Niemann-Pick disease (NPD) market are focusing on developing advanced treatments, such as combination therapy, to enhance treatment efficacy and improve patient outcomes. This method involves the administration of two or more therapeutic agents or treatment strategies to address a disease or medical condition, aiming to improve effectiveness and minimize resistance to single-agent therapy (monotherapy). For instance, in September 2024, Zevra Therapeutics Inc., a US-based biopharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for MIPLYFFA, in combination with miglustat, for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in both adult and pediatric patients aged 2 years and older. MIPLYFFA (arimoclomol) functions by enhancing the production of heat shock proteins (HSPs), which aid in clearing toxic lipid buildup and protecting neurons from damage. Meanwhile, miglustat inhibits glucosylceramide synthase, thereby reducing lipid accumulation. Together, the two therapies help slow the progression of neurological decline in NPC patients.

Which Major Industry Participants Are Leading The Niemann-Pick Disease (NPD) Market Growth?

Major companies operating in the niemann-pick disease (npd) market are Sanofi S.A., Mayo Clinic, Cincinnati Children’s Hospital Medical Center, Boston Children’s Hospital, Mallinckrodt Pharmaceuticals plc, Myriad Genetics, CENTOGENE N.V., The Florey Institute of Neuroscience and Mental Health, National Organization for Rare Disorders (NORD), Evox Therapeutics Limited, Bloomsbury Genetic Therapies Ltd., Cyclo Therapeutics Inc., CarelonRx, Rainbow Children’s Hospital, Vtesse Inc., Orphazyme A/S, Zebra Biologics, Sarepta Therapeutics Inc., Takeda Pharmaceutical Company Limited, Pfizer Inc., Novartis International AG, Ultragenyx Pharmaceutical Inc., Passage Bio, Amicus Therapeutics Inc., PTC Therapeutics, SOM Biotech, ENDECE, StrideBio, Mandos Health, BioMarin Pharmaceutical Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/niemann-pick-disease-npd-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The Niemann-Pick Disease (NPD) Market?

North America was the largest region in the niemann-pick disease (NPD) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the niemann-pick disease (npd) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Niemann-Pick Disease (NPD) Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=23457&type=smp

Browse Through More Reports Similar to the Global Niemann-Pick Disease (NPD) Market 2026, By The Business Research Company

Kidney Disease Market Report 2026

https://www.thebusinessresearchcompany.com/report/kidney-disease-global-market-report

Rare Neurological Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-neurological-disease-treatment-global-market-report

Alpers Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/alpers-disease-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model